Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
BNTX Analyst Ratings
Strong Buy
14 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
BNTX Stock 12 Month Forecast
Average Price Target
$139.63
▲(44.66% Upside)
| Highest Price Target$171.00 | Average Price Target$139.63 | Lowest Price Target$110.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
Reiterated
04/14/25
H.C. Wainwright
Reiterated
04/01/25
Truist Financial
Reiterated
03/31/25
Leerink Partners
Reiterated
03/30/25
Wells Fargo
Reiterated
03/28/25
Bank of America Securities
Reiterated
03/28/25
Deutsche Bank
Reiterated
03/26/25
Goldman Sachs
Reiterated
03/21/25
Berenberg Bank
Reiterated
03/21/25
Canaccord Genuity
Reiterated
03/20/25
Citi
$145
Buy
50.23%
Upside
Initiated
03/13/25
BioNTech initiated with a Buy at CitiBioNTech initiated with a Buy at Citi
BMO Capital
$130→$143
Buy
48.16%
Upside
Reiterated
03/11/25
BioNTech price target raised to $143 from $130 at BMO CapitalBioNTech price target raised to $143 from $130 at BMO Capital
TD Cowen
$122→$110
Hold
13.97%
Upside
Reiterated
03/11/25
Cautious Outlook for BioNTech SE Amid Revenue Shortfall and Oncology Pipeline UncertaintyWe are updating our model to trim Comirnaty estimates and align with FY25 guidance (€1.7M - €2.2M total revs, €2.6M - €2.8M R&D, €650M - €750M SG&A, and €250M - €350M CapEx). We expect Pfizer/BioNTech will maintain their ~60% market share in the US moving forward and at least a ~75% share in the EU in FY25+ but arelowering our near-term COVID-19 sales. We now model €4.2B (-€60M), €4.2B (-€117M), €4.2B (-€118M), and €4.3B (-€119M) in FY25-‘28 global Comirnaty sales which would yield €2.0B (-€17M), €1.9B (-€43M), €2.0B (- €44M), and €2.0B (-€44M) in sales to BioNTech.
UBS
$131→$115
Hold
19.15%
Upside
Reiterated
03/11/25
UBS Sticks to Their Hold Rating for BioNTech SE (BNTX)
J.P. Morgan
$120
Hold
24.33%
Upside
Reiterated
03/10/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (NASDAQ: BNTX) and Trevi Therapeutics (NASDAQ: TRVI)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
Reiterated
04/14/25
H.C. Wainwright
Reiterated
04/01/25
Truist Financial
Reiterated
03/31/25
Leerink Partners
Reiterated
03/30/25
Wells Fargo
Reiterated
03/28/25
Bank of America Securities
Reiterated
03/28/25
Deutsche Bank
Reiterated
03/26/25
Goldman Sachs
Reiterated
03/21/25
Berenberg Bank
Reiterated
03/21/25
Canaccord Genuity
Reiterated
03/20/25
Citi
$145
Buy
50.23%
Upside
Initiated
03/13/25
BioNTech initiated with a Buy at CitiBioNTech initiated with a Buy at Citi
BMO Capital
$130→$143
Buy
48.16%
Upside
Reiterated
03/11/25
BioNTech price target raised to $143 from $130 at BMO CapitalBioNTech price target raised to $143 from $130 at BMO Capital
TD Cowen
$122→$110
Hold
13.97%
Upside
Reiterated
03/11/25
Cautious Outlook for BioNTech SE Amid Revenue Shortfall and Oncology Pipeline UncertaintyWe are updating our model to trim Comirnaty estimates and align with FY25 guidance (€1.7M - €2.2M total revs, €2.6M - €2.8M R&D, €650M - €750M SG&A, and €250M - €350M CapEx). We expect Pfizer/BioNTech will maintain their ~60% market share in the US moving forward and at least a ~75% share in the EU in FY25+ but arelowering our near-term COVID-19 sales. We now model €4.2B (-€60M), €4.2B (-€117M), €4.2B (-€118M), and €4.3B (-€119M) in FY25-‘28 global Comirnaty sales which would yield €2.0B (-€17M), €1.9B (-€43M), €2.0B (- €44M), and €2.0B (-€44M) in sales to BioNTech.
UBS
$131→$115
Hold
19.15%
Upside
Reiterated
03/11/25
UBS Sticks to Their Hold Rating for BioNTech SE (BNTX)
J.P. Morgan
$120
Hold
24.33%
Upside
Reiterated
03/10/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (NASDAQ: BNTX) and Trevi Therapeutics (NASDAQ: TRVI)
Best Analysts Covering BioNTech SE
Which Analyst Should I Follow If I Want to Buy BNTX and Sell After:
1 Month
xxx
Success Rate
14/26 ratings generated profit
Average Return
+1.01%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +1.01% per trade.
3 Months
xxx
Success Rate
11/26 ratings generated profit
Average Return
+0.15%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.31% of your transactions generating a profit, with an average return of +0.15% per trade.
1 Year
Success Rate
6/10 ratings generated profit
Average Return
+2.45%
reiterated a buy rating last month
Copying Etzer Darout's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +2.45% per trade.
2 Years
xxx
Success Rate
6/10 ratings generated profit
Average Return
+0.34%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +0.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
BNTX Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
4
3
0
6
7
Buy
41
44
27
34
25
Hold
13
11
4
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
58
58
31
44
35
Each month's total comprises the sum of three months' worth of ratings.
BNTX Financial Forecast
BNTX Stock Forecast FAQ
What is BNTX’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is $139.63.
What is BNTX’s upside potential, based on the analysts’ average price target?
BioNTech SE has 44.66% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BNTX a Buy, Sell or Hold?
BioNTech SE has a consensus rating of Strong Buy which is based on 14 buy ratings, 3 hold ratings and 0 sell ratings.
What is BioNTech SE’s price target?
The average price target for BioNTech SE is $139.63. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $171.00 ,the lowest forecast is $110.00. The average price target represents 44.66% Increase from the current price of $96.52.
The highest analyst price target is $171.00 ,the lowest forecast is $110.00. The average price target represents 44.66% Increase from the current price of $96.52.
What do analysts say about BioNTech SE?
BioNTech SE’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of BNTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.